LinaTech — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

LinaTech is a private, commercial-stage company that has evolved from its 1998 founding into a developer and manufacturer of integrated radiotherapy systems. Its core technology platform centers on advanced linear accelerators (like the VenusX) and specialized multi-leaf collimators (like the TiGRT MLC-CC51/D2SRS), combined with proprietary treatment planning and image viewing software. The company targets the global radiation oncology market by offering solutions that modernize existing infrastructure and enable precise treatments like SRS/SBRT, with direct sales and support through its international offices.

Oncology

Technology Platform

Integrated radiotherapy platform featuring the VenusX medical linear accelerator with orthogonal double-layer MLC and AI-driven QA, the TiGRT D2SRS add-on MLC for SRS/SBRT retrofits, and the TiGRT suite of treatment planning and image viewing software.

Opportunities

Significant opportunity in retrofitting older linear accelerators with its D2SRS MLC system to enable advanced SRS/SBRT treatments, extending equipment life at a lower cost than new machines.

Growing global demand for cost-effective, precise radiotherapy in emerging markets aligns well with its integrated platform and manufacturing capabilities.

Risk Factors

Faces intense competition from large, established players like Varian and Elekta, with risks of technological obsolescence.

Regulatory hurdles in key international markets could delay growth and market access, while execution quality across its global service network is critical for customer retention.

Competitive Landscape

Operates in a highly competitive market dominated by Varian (Siemens Healthineers) and Elekta. LinaTech differentiates through its retrofit-focused MLC technology for legacy systems and a fully integrated, cost-competitive LINAC and software suite, positioning it as a niche player targeting cost-sensitive segments and upgrade markets.

More companies in Radiopharmaceuticals →More companies in United States →